| 000 | 01427 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517090717.0 | ||
| 264 | 0 | _c20161213 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a2284-0729 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCraxì, L | |
| 245 | 0 | 0 |
_aPrioritization of high-cost new drugs for HCV: making sustainability ethical. _h[electronic resource] |
| 260 |
_bEuropean review for medical and pharmacological sciences _c2016 |
||
| 300 |
_a1044-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiviral Agents _xeconomics |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
| 650 | 0 | 4 |
_aDrug Costs _xethics |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHealth Priorities _xeconomics |
| 650 | 0 | 4 | _aHepacivirus |
| 650 | 0 | 4 |
_aHepatitis C _xdrug therapy |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xeconomics |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aQuality of Life |
| 700 | 1 | _aSacchini, D | |
| 700 | 1 | _aRefolo, P | |
| 700 | 1 | _aMinacori, R | |
| 700 | 1 | _aDaloiso, V | |
| 700 | 1 | _aRicci, G | |
| 700 | 1 | _aBruno, R | |
| 700 | 1 | _aCammà, C | |
| 700 | 1 | _aCicchetti, A | |
| 700 | 1 | _aGasbarrini, A | |
| 700 | 1 | _aSpagnolo, A G | |
| 773 | 0 |
_tEuropean review for medical and pharmacological sciences _gvol. 20 _gno. 6 _gp. 1044-51 |
|
| 999 |
_c25897373 _d25897373 |
||